- Stocks
- Healthcare
- NYSE: EBS

Price (delayed)

$58.80

Market cap

$3.15B

P/E Ratio

8.02

Dividend/share

N/A

EPS

$7.33

Enterprise value

$3.46B

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Website: https://emergentbiosolutions.com/

The P/E is 88% lower than the 5-year quarterly average of 66.8 and 62% lower than the last 4 quarters average of 21.2

EBS's gross profit has soared by 68% year-on-year and by 12% since the previous quarter

EBS's quick ratio is up by 19% YoY but it is down by 11% QoQ

Emergent BioSolutions's debt has increased by 9% YoY

What are the main financial stats of EBS

Market
Valuations
Earnings

Shares outstanding

53.59M

Market cap

$3.15B

Enterprise value

$3.46B

Price to earnings (P/E)

8.02

Price to book (P/B)

2.06

Price to sales (P/S)

1.84

EV/EBIT

6.35

EV/EBITDA

5.25

EV/Sales

2.03

Revenue

$1.71B

EBIT

$544.9M

EBITDA

$659.9M

Free cash flow

$310.4M

Per share
Balance sheet
Liquidity

EPS

$7.33

Free cash flow per share

$5.82

Book value per share

$28.57

Revenue per share

$32.01

TBVPS

$37.25

Total assets

$2.9B

Total liabilities

$1.38B

Debt

$859.1M

Equity

$1.52B

Working capital

$810.9M

Debt to equity

0.56

Current ratio

3.19

Quick ratio

1.98

Net debt/EBITDA

0.47

Margins
Efficiency
Dividend

EBITDA margin

38.7%

Gross margin

68%

Net margin

22.7%

Operating margin

31.7%

Return on assets

14.3%

Return on equity

28.6%

Return on invested capital

29.8%

Return on capital employed

21.5%

Return on sales

31.9%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Emergent BioSolutions stock price performed over time

Intraday

-1.79%

1 week

-0.51%

1 month

-23.98%

1 year

-30.46%

YTD

-34.38%

QTD

-36.71%

How have Emergent BioSolutions's revenue and profit performed over time

Revenue

$1.71B

Gross profit

$1.16B

Operating income

$540.8M

Net income

$387.3M

Gross margin

68%

Net margin

22.7%

The company's operating margin has surged by 171% YoY and by 14% QoQ

EBS's gross profit has soared by 68% year-on-year and by 12% since the previous quarter

The company's revenue has surged by 54% YoY and by 10% QoQ

The net income has grown by 27% from the previous quarter

What is Emergent BioSolutions's growth rate over time

What is Emergent BioSolutions stock price valuation

P/E

8.02

P/B

2.06

P/S

1.84

EV/EBIT

6.35

EV/EBITDA

5.25

EV/Sales

2.03

The P/E is 88% lower than the 5-year quarterly average of 66.8 and 62% lower than the last 4 quarters average of 21.2

EBS's EPS is up by 27% since the previous quarter

The price to book (P/B) is 43% lower than the last 4 quarters average of 3.6 and 24% lower than the 5-year quarterly average of 2.7

EBS's equity is up by 42% year-on-year and by 5% since the previous quarter

The company's revenue has surged by 54% YoY and by 10% QoQ

The P/S is 44% below the last 4 quarters average of 3.3 and 43% below the 5-year quarterly average of 3.2

How efficient is Emergent BioSolutions business performance

EBS's ROS has soared by 168% year-on-year and by 13% since the previous quarter

EBS's ROIC is up by 21% QoQ

The company's return on assets rose by 20% QoQ

EBS's return on equity is up by 17% since the previous quarter

What is EBS's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for EBS.

How did Emergent BioSolutions financials performed over time

The total assets is 111% more than the total liabilities

The total assets has grown by 27% YoY

EBS's quick ratio is up by 19% YoY but it is down by 11% QoQ

Emergent BioSolutions's debt is 44% lower than its equity

EBS's equity is up by 42% year-on-year and by 5% since the previous quarter

The debt to equity has decreased by 23% YoY and by 7% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.